Plants and human health in the twenty-first century.

By I. Raskin, D. Ribnicky, S. Komarnytsky, Nebojša Ilić, A. Poulev, N. Borisjuk, Anita Brinker, D. Moreno, C. Ripoll, N. Yakoby and 4 more. Trends in Biotechnology, 2002

931 citations recorded by the source corpus.

Subfields: Biotechnology, Food Science, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/df1ac8b22628e0c6647046d291421a857041f47c

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Biotechnology

1. D. Newman
2. G. Cragg
3. R. Fischer
4. A. Demain
5. R. Twyman
6. Preeti Vaishnav

In Molecular Biology

1. G. Cragg
2. D. Newman
3. R. Fischer
4. A. Demain
5. R. Twyman
6. Preeti Vaishnav
7. A. Harvey
8. M. Gordaliza

Citations in the corpus

• NATURAL PRODUCTS: A CONTINUING SOURCE OF NOVEL DRUG LEADS (2013, background): “Despite the intensive investigation of terrestrial flora, it is estimated that only 6% of the approximately 300,000 species (some estimates are as high as 500,000 species) of higher plants have been systematically investigated, pharmacologically, and only some 15% phytochemically [8, 102, 103].”
• Natural products for cancer chemotherapy (2011, background): “Terpenes number 30 500 and as pharmaceuticals had a market of $12 billion in 2002 (Verpoorte, 2000; Raskin et al., 2002).”
• Achieving the Balance between ROS and Antioxidants: When to Use the Synthetic Antioxidants (2013, background): “In the USA, food supplements represent a market of over $7 billion/year [27] and exceed $30 billion worldwide [28].”
• The biosafety of molecular farming in plants (2003, background): “From a commercial point of view, one of the major benefits of plants is the reduced set-up and running costs (Raskin et al., 2002).”